Global Insulin Secretagogue Market Size, Share, and COVID-19 Impact Analysis, By Type (Sulfonylurea, Meglitinides, and Others), By Route Of Administration (Oral, Parenteral, and Others), By End Users (Hospitals, Specialty Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Insulin Secretagogue Market Size Insights Forecasts to 2035

• The Global Insulin Secretagogue Market Size Was Estimated at USD 2.53 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.73% from 2025 to 2035
• The Worldwide Insulin Secretagogue Market Size is Expected to Reach USD 6.35 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Insulin Secretagogue Market Size was worth around USD 2.53 Billion in 2024 and is predicted to grow to around USD 6.35 Billion by 2035 with a compound annual growth rate (CAGR) of 8.73% from 2025 and 2035. The market for insulin secretagogue has a number of opportunities to grow due to ongoing research studies on insulin secretagogue-based medications. Further, there is upsurging advancement in small molecule insulin secretagogues for diabetes treatment for effective diabetes treatment.  

Market Overview

The Global Insulin Secretagogue Industry focuses on the medications (sulfonylureas, glinides, DPP-4 inhibitors) that stimulate the pancreas to produce more insulin for type 2 diabetes management. The rising diabetes prevalence and demand for affordable oral therapies are driving the industry growth. An insulin secretagogue defined as substance stimulating the secretion of insulin from the pancreas, contributing to the regulation of blood glucose levels. In the market, there is a surging use of CGM (continuous glucose monitoring) that promote personalized dosing and the development of agents targeting specific pancreatic receptors, effectively managing postprandial glucose. Market expansion and biotech innovation are anticipated as a result of growing R&D expenditure by major players like Avant Technologies, Novo Nordisk, Eledon Pharmaceuticals, and other companies.  

Report Coverage

This research report categorizes the Insulin Secretagogue Market Size based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Insulin Secretagogue Market Size. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Insulin Secretagogue Market Size. 

Driving Factors

The rising prevalence of diabetes is a key factor driving market demand, with approximately 47% of patients using insulin secretagogues for diabetes management. In 2021, the global prevalence of diabetes among individuals aged 20–79 was estimated at 10.5% (536.6 million people) and is projected to increase to 12.2% (783.2 million people) by 2045.

The growing adoption of oral antidiabetic insulin secretagogues—primarily sulfonylureas and meglitinides—often in combination with metformin for managing fasting and postprandial glucose levels, is further propelling market growth. Additionally, advancements in drug formulations, including nanoparticulate drug delivery systems, along with increasing awareness of diabetes management, are contributing to market expansion.

Restraining Factors

The Insulin Secretagogue Market faces restraints such as adverse side effects and stringent regulatory requirements. Furthermore, competition from newer and more effective antidiabetic drug classes, along with declining efficacy over prolonged use, poses challenges to overall market growth.

Market Segmentation

The Insulin Secretagogue Market Size share is classified into type, route of administration, and end users.   

• The sulfonylurea segment dominated the market with the largest share of about 46.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the Insulin Secretagogue Market Size is divided into sulfonylurea, meglitinides, and others. Among these, the sulfonylurea segment dominated the market with the largest share of about 46.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Sulfonylureas class of drugs, act by directly stimulating the pancreatic beta cells to secrete more insulin regardless of blood glucose levels. The increased preference for sulfonylureas due to their effectiveness, accessibility, and affordability is promoting the market growth in the sulfonylurea segment.

• The oral segment accounted for the largest share of over 50.0% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the Insulin Secretagogue Market Size is divided into oral, parenteral, and others. Among these, the oral segment accounted for the largest share of over 50.0% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Insulin secretagogue are typically taken orally before meals. The upsurging trend of home-based care with telemedicine-driven monitoring, patient education and preference for less invasive treatment are anticipated to propel the market demand.

• The hospitals segment accounted for the dominant share of over 50.0% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end users, the Insulin Secretagogue Market Size is divided into hospitals, specialty clinics, and others. Among these, the hospitals segment accounted for the dominant share of over 50.0% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. For ensuring the safe and effective implementation of inpatient hyperglycemic control and insulin usage, the hospital pharmacist plays an important role. Further, hospitals are central to clinical trials and post-marketing studies. Hospital formularies and bulk procurement practices, for steady supply and adoption, as well as continuous training for physicians and diabetes educators, are responsible factors for driving the market. 

Regional Segment Analysis of the Insulin Secretagogue Market Size

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the Insulin Secretagogue Market Size over the predicted timeframe.

North America is anticipated to hold the largest share of about 39.9% in the Insulin Secretagogue Market Size over the predicted timeframe. The market ecosystem in North America is strong, with cutting-edge technology in diabetes care for personalized and user-friendly insulin delivery. The market demand for insulin secretagogue has been driven by the innovative insulin secretagogue products and partnerships with other industry players, for promoting awareness. For instance, in January 2025, the American Diabetes Association and Xeris Pharmaceuticals, a national supporter of the ADA, announced a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia. The U.S. is capturing the dominant market share of about 42.0% within the region in 2024, due to the increased prevalence of diabetes and the presence of well-established healthcare infrastructure, for providing effective patient care.

Asia Pacific is expected to grow at a rapid CAGR of about 22.0% in the Insulin Secretagogue Market Size during the forecast period. The Asia Pacific area has a thriving market for insulin secretagogue due to the increasing prevalence of diabetes and lifestyle-related disorders like obesity. Increased accessibility of oral antidiabetic therapies of insulin secretagogues via expanding hospital networks, specialty clinics, and pharmacy networks in the region is responsible for propelling the market. India is leading the Asia Pacific Insulin Secretagogue Market Size, with the largest revenue share in the region, driven by an increasing number of diabetes patients and preference for affordable oral insulin secretagogue medications.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Insulin Secretagogue Market Size, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lilly USA, LLC.
• Novo Nordisk A/S
• Sanofi
• Merck & Co., Inc.
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Biocon Ltd.
• Abbott
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Cadila Pharmaceuticals Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In January 2026, Viatris Inc., a global healthcare company, announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment.

• In October 2023, Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg.

• In October 2023, as per the study EASD (European Association for the Study of Diabetes), food insecurity doubles the rate of severe hypoglycemia in diabetic adults, especially among those using insulin and/or secretagogues.  

• In June 2023, Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration had approved INPEFA, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Insulin Secretagogue Market Size based on the below-mentioned segments:

Global Insulin Secretagogue Market Size, By Type  

• Sulfonylurea
• Meglitinides
• Others

Global Insulin Secretagogue Market Size, By Route Of Administration

• Oral
• Parenteral
• Others

Global Insulin Secretagogue Market Size, By End Users

• Hospitals
• Specialty Clinics
• Others

Global Insulin Secretagogue Market Size, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa